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Association of coagulation 
dysfunction with cardiac injury 
among hospitalized patients 
with COVID‑19
Liang Chen1,8, Wei Hu2,8, Xiaoxiao Guo2,8, Ping Zhao3, Jia Tang2, Yuwei Gu2, Ninghao Huang3, 
Chao Wang2, An Cui2, Dian Zhang2, Linjie Hu3, Yi Feng4, Shengshou Hu1,9, Mingquan Chen2*, 
Firat Duru5,6* & Chenglong Xiong3,7*
Cardiac injury is a common complication of the coronavirus disease 2019 (COVID‑19), and is associated 
with adverse clinical outcomes. In this study, we aimed to reveal the association of cardiac injury 
with coagulation dysfunction. We enrolled 181 consecutive patients who were hospitalized with 
COVID‑19, and studied the clinical characteristics and outcome of these patients. Cardiac biomarkers 
high‑sensitivity troponin I (hs‑cTnI), myohemoglobin and creatine kinase‑myocardial band (CK‑MB) 
were assessed in all patients. The clinical outcomes were defined as hospital discharge or death. 
The median age of the study cohort was 55 (IQR, 46–65) years, and 102 (56.4%) were males. Forty‑
two of the 181 patients (23.2%) had cardiac injury. Old age, high leukocyte count, and high levels 
of aspartate transaminase (AST), D‑dimer and serum ferritin were significantly associated with 
cardiac injury. Multivariate regression analysis revealed old age and elevated D‑dimer levels as being 
strong risk predictors of in‑hospital mortality. Interleukin 6 (IL6) levels were comparable in patients 
with or without cardiac injury. Serial observations of coagulation parameters demonstrated highly 
synchronous alterations of D‑dimer along with progression to cardiac injury. Cardiac injury is a 
common complication of COVID‑19 and is an independent risk factor for in‑hospital mortality. Old age, 
high leukocyte count, and high levels of AST, D‑dimer and serum ferritin are significantly associated 
with cardiac injury, whereas IL6 are not. Therefore, the pathogenesis of cardiac injury in COVID‑19 
may be primarily due to coagulation dysfunction along with microvascular injury.
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2)1, has resulted in considerable morbidity and mortality in millions of infected 
patients. Many studies have already described the clinical characteristics of patients with COVID-192–5. The 
overall mortality of the COVID-19 was determined to be 2.3% among general laboratory-confirmed  cases6, but 
the fatality rate was more than 10% among hospitalized patients, and even reached to 40% among critically ill 
 cases5. Cardiac injury, manifesting as elevation of troponin I (TnI) and decline of left ventricular ejection frac-
tion, has been observed as a common complication in 10–30% of hospitalized cases, significantly increasing 
the severity of COVID-19. It was also demonstrated to be an independent risk factor for  mortality5,7,8. Thus, 
understanding cardiac involvement and its monitoring in the clinical setting are of utmost importance for risk 
stratification and management of infected patients.
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The pathogenic mechanisms underlying cardiac injury in COVID-19 remain unclear. Multiple hypotheses 
have been proposed to be potentially associated with cardiac injury, such as myocarditis directly induced by the 
virus through angiotensin-converting enzyme 2 (ACE2)9,10, the putative viral receptor of SARS-COV-211. Other 
proposed mechanisms include cardiomyocyte damage induced by inflammatory cytokines or hypoxemia due 
to respiratory  dysfunction12 but the association of cardiac injury with these factors has not been systematically 
illuminated. In this study, we aimed to reveal the mechanisms of cardiac involvement and its association with 
coagulation dysfunction, and identify the potential risk factors for cardiac injury in hospitalized patients with 
COVID-19.
Results
Patient characteristics and laboratory findings. Data from 181 consecutive patients hospitalized 
with COVID-19 were enrolled in this study, including 42 patients (23.2%) with cardiac injury and 139 patients 
(76.8%) without cardiac injury (Table 1). The median age of the patients in the overall cohort was 55 (IQR, 
46–65) years, and 102 (56.4%) were males. There were more males in patients with cardiac injury, and these 
patients were older and had baseline comorbidities, such as hypertension, coronary heart disease, arrhythmias 
and cancer, more often.
The duration from the beginning of symptoms to hospital admission was similar in patients with and with-
out cardiac injury (median [IQR] days, 10 [7, 15] vs 10 [7, 15], P = 0.925). In addition to significantly elevated 
hs-TnI, myohemoglobin and CK-MB, patients with cardiac injury showed higher leukocyte count and higher 
levels of aspartate transaminase, high-sensitivity C-reactive protein (hs-CRP), D-dimer, procalcitonin, serum 
ferritin and lactic dehydrogenase (LDH), and lower levels of SpO2, platelets, lymphocytes, and albumin. All these 
findings were consistent with deteriorated conditions of the patients. Serum creatinine levels, lipids, erythro-
cyte sedimentation rate (ESR), and Interleukin 6 (IL6) (8.36 [6.37, 12.12] vs 10.41 [6.79, 15.21], P = 0.089) were 
comparable between the two groups.
Clinical course and outcomes. The treatment, complications and outcomes of the COVID-19 patients are 
shown in Table 2. The majority of patients were treated with anti-viral medications (95.0%), antibiotics (96.1%) 
and oxygen inhalation (74.6%). The patients in the cardiac injury group more often required glucocorticoids 
(29 [69.0%] vs 44 [31.7%], P < 0.001), immunoglobulin therapy (18 [42.9%] vs 26 [18.7%], P = 0.001) and non-
invasive ventilation (20 [47.6%] vs 14 [10.1%], P < 0.001). Moreover, cardiac injury group had significantly more 
frequent hypoproteinemia (22 [52.4%] vs 33 [23.7%], P < 0.001) and ARDS (14 [33.3%] vs 12 [8.6%], P < 0.001), 
and more often progressed to severe disease (36 [85.7%] vs 47 [33.8%], P < 0.001). As a coincident, the mortality 
rate was higher in the cardiac injury group as compared to non-cardiac injury group (22 [52.4%] vs 12 [8.6%], 
P < 0.001). Kaplan–Meier survival curves are shown in Fig. 1 (Log rank, P < 0.001).
Predictors of in‑hospital outcome. To examine the role of cardiac injury for the risk stratification of 
in-hospital COVID-19 mortality, we systematically compared the clinical characteristics between survivors 
(n = 147) and non-survivors (n = 34) (Table S1). Multivariable Cox regression analysis revealed that two of the 
three cardiac biomarkers was independently associated with the prognosis, with hazard ratios [95%CI] for 
myohemoglobin, and CK-MB being 1.41 ([1.11, 1.80], P = 0.005), and 1.50 ([1.10, 2.06], P = 0.012), respectively 
(Table 3). When we used binary variable as cardiac injury defined by elevation of cardiac biomarkers, it was 
also an independent predictor for mortality (2.63 [1.38, 5.65], P = 0.016). Other predictors such as age, hs-CRP, 
and D-dimer were also associated with poor prognosis in at least one model. ROC curve analysis demonstrated 
that these variables, and especially D-dimer and myohemoglobin, could independently well predict adverse 
outcomes (Fig. 2).
Predictors of cardiac injury. As a next step, we performed Spearman correlation and revealed the poten-
tial links between cardiac injury biomarkers and other clinical characteristics such as SpO2, leukocytes, plate-
lets, lymphocytes, aspartate transaminase (AST), LDH, hs-CRP, procalcitonin, D-dimer, serum ferritin and ESR 
(Table 4). However, the associations between cytokine IL6 and cardiac biomarkers were limited (P = 0.01 with 
hs-TnI, P = 0.346 with myohemoglobin, and P = 0.226 with CK-MB).
To further examine the predictors of cardiac injury, we used two multivariable regression models, LASSO 
and logistic regression. In LASSO regression analysis, we identified four features with nonzero coefficients 
including old age, leukocytes, D-dimer and serum ferritin from a total of 15 related variables (Fig. 3). Logistic 
regression analysis also confirmed exactly the same four independent predictors of cardiac injury in patients with 
COVID-19 (Table S2, Fig. 4A). Each factor showed good discrimination of cardiac injury through ROC curve 
analysis (P < 0.001 in each factor), especially serum ferritin (AUC, 0.844) and D-dimer (AUC, 0.816) (Fig. 4B). 
We established a logistic regression model based on the combination of the four predictors, and the ROC curve 
showed excellent discrimination of cardiac injury (AUC, 0.896) with a sensitivity of 83.30% and specificity of 
85.30% (Fig. 4C).
Cardiac injury and coagulation. Considering the significant association of D-dimer with cardiac injury, 
we further validated the role of coagulation dysfunction in the development of cardiac injury. We involved a sub-
cohort containing 10 patients who were free of cardiac involvement at admission, but developed cardiac injury 
during later hospitalization. Serial testing of biomarkers in these patients revealed consistent elevation of car-
diac biomarkers, and three of them alleviated during follow-up (Fig. 5A–C). The inflammatory biomarkers IL6 
and hs-CRP were generally elevated among these patients, but no synchronous change (elevation or decrease) 
was observed consistent with cardiac injury (Fig. 5D,E). On the other hand, markers of coagulation function, 
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Table 1.  Clinical characteristics of patients with or without cardiac injury. ALT: alanine aminotransferase; 
AST: aspartate transaminase; BNP: B-type natriuretic peptide; CK-MB: creatine kinase-myocardial band; 
COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; ESR: erythrocyte 
sedimentation rate; HDL-C: high density lipoprotein cholesterol; hs-CRP: high-sensitivity C-reactive protein; 
LDH: Lactic dehydrogenase; LDL-C: low density lipoprotein cholesterol. *Extra levels of hs-CRP were shown 
as > 160; †extra levels of serum ferritin shown as > 2000.
Characteristics Total (n = 181) Non-cardiac injury (n = 139) Cardiac injury (n = 42) P value
Age, years 55 (46, 65) 54 (43, 64) 63.5 (50, 71) 0.002
Male 102 (56.4) 71 (51.1) 31 (73.8) 0.009
Heart rate 88 (80, 96) 87 (80, 95) 89.5 (82, 96) 0.142
Systolic pressure, mmHg 128 (116, 142) 128 (116, 140) 133.5 (119, 145) 0.385
Diastolic pressure, mmHg 80 (72, 85) 80 (71, 85) 82 (72, 86) 0.793
Smoking 15 (8.3) 9 (6.5) 6 (14.3) 0.118
Comorbidities, n(%)
Hypertension 54 (29.8) 37 (26.6) 17 (40.5) 0.086
Diabetes 29 (16) 21 (15.1) 8 (19) 0.543
Coronary heart disease 8 (4.4) 4 (2.9) 4 (9.5) 0.086
Arrhythmias 5 (2.8) 2 (1.4) 3 (7.1) 0.083
COPD 8 (4.4) 4 (2.9) 4 (9.5) 0.086
Cancer 7 (3.9) 3 (2.2) 4 (9.5) 0.052
Infective disease 10 (5.5) 7 (5) 3 (7.1) 0.700
Lab findings, median (IQR)
SpO2 (%) 0.96 (0.9, 0.98) 0.97 (0.93, 0.98) 0.89 (0.77, 0.94) < 0.001
Leukocytes, × 103/μL 5.61 (4.08, 8.48) 5.27 (3.9, 7.33) 8.35 (5.02, 11.26) 0.001
Erythrocytes, × 106/μL 4.19 (3.86, 4.56) 4.19 (3.88, 4.53) 4.12 (3.84, 4.58) 0.922
Hemoglobin, g/dL 129 (117, 136) 128 (118, 136) 129.5 (116, 136) 0.810
Platelets, × 103/μL 191 (147, 251) 203 (153, 269) 152 (125, 208) 0.002
Lymphocytes, × 103/μL 0.98 (0.67, 1.61) 1.17 (0.8, 1.72) 0.76 (0.48, 0.95) < 0.001
Neutrophils, × 103/μL 5.81 (2.64, 7.49) 4.72 (2.43, 5.43) 9.4 (4.14, 11.48) < 0.001
Monocytes, × 103/μL 0.39 (0.28, 0.47) 0.39 (0.28, 0.49) 0.4 (0.21, 0.45) 0.160
Basophils, × 103/μL 0.02 (0.01, 0.02) 0.02 (0.01, 0.02) 0.03 (0, 0.02) 0.453
Eosnophils, × 103/μL 0.04 (0, 0.06) 0.05 (0, 0.07) 0.02 (0, 0.02) < 0.001
Creatinine, μmol/L 68.4 (56.7, 81.7) 67 (56.7, 78.2) 73.6 (61, 93) 0.061
eGFR, × mL/(min × 1.73  m2) 106.13 (91.02, 127.69) 110.31 (95.06, 127.69) 102.12 (83.37, 129.5) 0.165
Albumin, g/L 33.1 (29.2, 36.5) 33.4 (30.4, 37.3) 30.6 (27.1, 33.5) < 0.001
Total bilirubin, μmol/L 12.6 (9.4, 15.9) 12.4 (9.3, 15.5) 13.55 (9.6, 19.1) 0.207
AST, U/L 34 (25, 45) 32 (24, 41) 45 (32, 58) < 0.001
ALT, U/L 33 (22, 46) 31 (20, 45) 37 (25, 54) 0.129
Cholesterol, mmol/L 3.88 (3.19, 4.53) 3.95 (3.22, 4.53) 3.69 (3.12, 4.62) 0.222
Triglyceride, mmol/L 1.2 (0.93, 1.76) 1.2 (0.9, 1.76) 1.21 (0.97, 2.16) 0.661
LDL-C, mmol/L 2.21 (1.74, 2.65) 2.22 (1.76, 2.68) 2.21 (1.55, 2.53) 0.351
HDL-C, mmol/L 1.03 (0.82, 1.23) 1.06 (0.86, 1.23) 0.9 (0.77, 1.24) 0.075
LDH,U/L 352 (236, 473) 244 (200, 346) 443.5 (318, 709) < 0.001
hs-CRP, mg/L* 25.9 (6.2, 86.7) 15.1 (4.2, 66.4) 67.75 (25.4, 160) < 0.001
Procalcitonin, ng/mL 0.05 (0.05, 0.1) 0.05 (0.05, 0.05) 0.11 (0.05, 0.25) < 0.001
D-dimer, μg/mL 0.73 (0.36, 2.95) 0.58 (0.3, 1.21) 5.86 (0.81, 28.89) < 0.001
Serum ferritin, ng/mL† 609.88 (304.31, 1217.78) 459.57 (262.78, 813.17) 1375.8 (967.81, 2000) < 0.001
ESR, mm/h 42.05 (27.3, 63) 40 (27, 61) 48.2 (38.5, 66) 0.054
Interleukin 6, pg/mL 8.66 (6.65, 12.17) 8.36 (6.37, 12.12) 10.41 (6.79, 15.21) 0.089
hs-TnI, pg/mL 3.9 (1.2, 12.5) 2.9 (1, 6.9) 19.35 (9.4, 185.3) < 0.001
Myohemoglobin, ng/mL 46.8 (28.2, 88.25) 37.9 (26.2, 65.2) 157.65 (120.4, 238) < 0.001
BNP, pg/mL 31.1 (10.03, 77.37) 31.1 (10, 66.2) 59.3 (26.7, 256.7) 0.001
Creatine kinase, U/L 84 (55, 163) 76 (49, 122) 238 (97, 384) < 0.001
CK-MB, U/L 14 (10, 18) 13 (10, 16) 18 (14, 34) < 0.001
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Table 2.  Treatment, complications and clinical outcome of patients with COVID-19.
Characteristics Total (n = 142) Non-cardiac injury (n = 139) Cardiac injury (n = 42) P value
Time from onset to admission 10 (7.15) 10 (7.15) 10 (7.15) 1.000
Treatment
Antiviral drugs 172 (95) 132 (95) 40 (95.2) 1.000
Antibiotics 174 (96.1) 133 (95.7) 41 (97.6) 1.000
Glucocorticoids 73 (40.3) 44 (31.7) 29 (69) < 0.001
Immunoglobulin therapy 44 (24.3) 26 (18.7) 18 (42.9) 0.001
Oxygen inhalation 135 (74.6) 102 (73.4) 33 (78.6) 0.500
Noninvasive ventilation 34 (18.8) 14 (10.1) 20 (47.6) < 0.001
Invasive ventilation 2 (1.1) 0 (0) 2 (4.8) 0.053
Complications
ARDS 26 (14.4) 12 (8.6) 14 (33.3) < 0.001
Acute kidney injury 8 (4.4) 4 (2.9) 4 (9.5) 0.086
Hypoproteinemia 55 (30.4) 33 (23.7) 22 (52.4) < 0.001
Anemia 16 (8.8) 12 (8.6) 4 (9.5) 0.767
Hypoxemia 55 (30.4) 37 (26.6) 18 (42.9) 0.046
Arrhythmias 11 (6.1) 5 (3.6) 6 (14.3) 0.02
Clinical outcome
Critical condition 83 (45.9) 47 (33.8) 36 (85.7) < 0.001
Death 34 (18.8) 12(8.6) 22 (52.4) < 0.001










































Figure 1.  Kaplan–Meier curve. Kaplan–Meier curve for mortality of patients with or without cardiac injury 
during the time from blood testing (A) and symptom onset (B).
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D-dimer (P = 0.005) and fibrinogen degradation products (FDP) (P = 0.011), were significantly increased from 
the time of admission to the time of cardiac injury, while fibrinogen (P < 0.001) and aPTT (P = 0.012) were syn-
chronously decreased along with the progression of cardiac involvement (Fig. 5F–L). These results suggest that 
cardiac injury was closely accompanied by hypercoagulable state. In addition, the levels of D-dimer and FDP 
recovered back to initial state among the three patients with alleviated cardiac injury during follow-up, which 
were consistent with the dynamic alterations of cardiac biomarkers. The summary of discoveries from this study 
is shown in Fig. 6.
Discussion
This study systematically analyzed the occurrence cardiac injury and described its clinical predictors in patients 
with COVID-19. The major findings of this study include: (i) cardiac injury, which is manifested by elevation 
of cardiac biomarkers, is an independent risk factor for in-hospital mortality; (ii) old age, high leukocyte count, 
D-dimer and serum ferritin are significantly associated with cardiac injury; and (iii) the dynamic progression of 
cardiac injury is particularly correlated with coagulation dysfunction (elevated D-dimer and FDP and decreased 
fibrinogen). While two of the above findings (i and ii) confirm the results of previously reported studies, the 
latter (iii) is a novel and most important finding of this study (Fig. 6).
Cardiac injury associated with poor prognosis. The COVID-19 has widely spread since its first 
reported outbreak in December 2019 and has not been controlled to date. Previous studies have demonstrated 
that SARS-CoV-2 not only causes pneumonia, but also may result in multiple organ injury through systemic 
inflammation or due to direct attack of the virus via ACE2  receptor3,5,6,13. Cardiac injury has been reported to be 
common among COVID-19 patients, ranging from 7.2 to 27.8% of all hospitalized  patients7,8,14, and its incidence 
has been higher among patients who suffered from severe disease requiring intensive care unit (ICU) or in those 
who  died5,15. Pre-exiting comorbidities such as hypertension, coronary heart disease, and COPD have been 
identified as risk factors for cardiac  injury14. However, it was also observed that 11.8% of patients who died from 
COVID-19 had no baseline underlying cardiovascular condition, and despite that, these patients developed 
substantial cardiac  damage12. Interestingly, in our cohort, cardiac injury was more commonly observed in male 
patients than in females (P = 0.009), which could be partially explained by significantly higher rate of smokers 
among males in China, and by a recent observation that showed higher plasma concentration of ACE2 in men 
as compared to  women16.
Consistent with previous  studies7,8,14, our study confirmed that patients with cardiac injury had considerably 
higher in-hospital mortality rate (52.4%) than those who did not develop cardiac injury (8.6%). Moreover, several 
clinical parameters, such as old age, IL6 and coagulation parameters (especially D-dimer) have also been reported 
to be associated with adverse prognosis by retrospective cohort  studies17,18. However, there was no reported 
Table 3.  Multivariate Cox regression analysis on the risk factors associated with mortality in patients. Cardiac 
biomarkers were included in Model 1, 2, 3 separately as continuous variables. Cardiac injury was included in 
Model 4 as binary variable.
Variables
Model 1 Model 2 Model 3 Model 4
HR (95%CI) P value HR (95%CI) P value
HR
(95%CI) P value HR (95%CI) P value
Age 1.03 (1.01, 1.06) 0.016 0.083 0.014 0.058
COPD 0.053 0.093 0.030 0.063
SpO2, % 0.391 0.330 0.276 0.391
Leukocytes, × 103/
μL
0.696 0.903 0.770 0.696
Platelets, × 103/μL 0.215 0.103 0.070 0.215
Lymphocytes, × 103/
μL
0.304 0.464 0.439 0.304
AST, U/L 0.186 0.937 0.386 0.186
LDH,U/L 0.401 0.758 0.322 0.401
hs-CRP, mg/L 1.44 (1.12, 1.85) 0.004 1.39 (1.08, 1.79) 0.011 1.43 (1.12, 1.82) 0.004 1.44 (1.12, 1.85) 0.004
D-dimer, μg/mL 1.47 (1.28, 1.71) < 0.001 1.36 (1.18, 1.58) < 0.001 1.46 (1.26, 1.68) < 0.001 1.48 (1.28, 1.71) < 0.001
Serum ferritin, 
ng/mL
0.055 0.330 0.321 0.055
ESR, mm/h 0.288 0.115 0.420 0.288
Interleukin 6, pg/
mL
0.192 0.150 0.132 0.192
hs-TnI, pg/mL 0.218 – – –
Myohemoglobin, 
ng/mL
– 1.41 (1.11, 1.80) 0.005 – –
CK-MB, U/L – – 1.50 (1.10, 2.06) 0.012 –
Cardiac injury – – – 2.63 (1.38, 5.65) 0.016
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evidence to reveal the role and weight of cardiac injury in predicting prognosis compared to the other laboratory 
parameters. In present study, we included multiple associated factors in the multivariate regression model, and 
demonstrated the independent role of cardiac injury, defined by binary variable or continuous variable (hs-TnI, 
myohemoglobin and CK-MB), in predicting the risk for death. Meanwhile, old age, D-dimer and hs-CRP levels 























Variables AUC 95% CI P value
Age 0.661 0.564-0.758 0.002
hsCRP 0.72 0.641-0.798 <0.001
D-dimer 0.816 0.742-0.891 <0.001
hs-TnI 0.859 0.792-0.926 <0.001
Myohemoglobin 0.905 0.84-0.97 <0.001
CK-MB 0.759 0.675-0.843 <0.001
A
B
Figure 2.  Receiver operating characteristic (ROC) analysis of the prediction of in-hospital mortality. (A) ROC 
curve of age and laboratory biomarkers. (B) Area under the ROC curve (AUC) with 95% confidence interval 
(CI) of each variable. CK-MB, creatine kinase-myocardial band; hs-TnI, high sensitivity-cardiac troponin I; 
hs-CRP, high-sensitivity C-reactive protein.
Table 4.  Spearman correlation analysis between cardiac biomarkers and other laboratory findings.
Variable
hsTnI Myohemoglobin CK-MB
Spearman P value Spearman P value Spearman P value
Age 0.47 < 0.001 0.40 < 0.001 − 0.03 0.693
SpO2 − 0.48 < 0.001 − 0.45 < 0.001 − 0.23 0.002
Leukocytes 0.28 < 0.001 0.21 0.005 0.09 0.236
Platelets − 0.23 0.002 − 0.27 < 0.001 − 0.24 0.001
Lymphocytes − 0.26 < 0.001 − 0.31 < 0.001 − 0.29 < 0.001
AST 0.28 < 0.001 0.35 < 0.001 0.44 < 0.001
LDH 0.41 < 0.001 0.46 < 0.001 0.57 < 0.001
hs-CRP 0.45 < 0.001 0.42 < 0.001 0.28 < 0.001
PCT 0.42 < 0.001 0.39 < 0.001 0.37 < 0.001
D-dimer 0.47 < 0.001 0.40 < 0.001 0.15 0.035
Serum ferritin 0.50 < 0.001 0.57 < 0.001 0.35 < 0.001
ESR 0.21 0.004 0.15 0.04 0.15 0.042
IL6 0.19 0.010 0.07 0.346 − 0.09 0.226
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Figure 3.  Feature selection using the LASSO binary regression model to identify independent factors of cardiac 
injury. (A) Tuning parameter (λ) selection in the LASSO model used tenfold cross-validation via minimum 
criteria. The binomial deviance was plotted versus log (λ). Dotted vertical lines were drawn at the optimal values 
by using minimum criteria and the 1 standard error (1-SE criteria). (B) LASSO coefficient profiles of the 15 
features. A coefficient profile plot was produced against the log(λ) sequence. Dotted vertical line was drawn at 
the optimal λ at minimum criteria and 1 standard error (1-SE criteria). The model at 1-SE criteria was selected 
as the final model with 4 nonzero coefficients including age, leukocytes, D-dimer, and serum ferritin. LASSO, 
least absolute shrinkage and selection operator.
Variables Univariate Multivariate
OR (95%CI) P value OR (95%CI) P value
Age 1.04 (1.01,1.07) 0.002 1.06 (1.02,1.10) 0.002
Leukocytes 1.13 (1.05,1.22) 0.002 1.080 (1.004,1.156) 0.051
D-dimer 1.13 (1.07,1.19) <0.001 1.083 (1.030,1.139) 0.001







































Figure 4.  Receiver operating characteristic (ROC) analysis of the prediction of cardiac injury by multivariate 
regression model. (A) Univariate and multivariate logistic regression analysis of cardiac injury. (B) ROC curve 
of the prediction of cardiac injury by each variable. (C) ROC curve of the prediction of cardiac injury by the 
combined regression model of five variables. Area under the ROC curve (AUC) was 0.896, with a sensitivity of 
83.30% and specificity of 85.30%.
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Figure 5.  Dynamic changes of cardiac, inflammatory and coagulation biomarkers. The laboratory testing 
results were obtained from initial time on admission, to cardiac injury (CI) state manifested by elevation of 
cardiac biomarkers. The recovery state from three patients were also included. P value represented comparison 
of initial and cardiac injury state, by paired Student’s t-test. FDP, fibrinogen degradation products; aPTT, 











Figure 6.  Work Summary. The patients with COVID-19 could have multiple manifestations like elder age, 
coagulation dysfunction, cardiac injury, inflammatory and hypoxemia, of which the former four factors 
are associated with in-hospital mortality. In the meantime, cardiac injury is associated with senior age and 
coagulation, but not directly associated with inflammatory response and hypoxemia.
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Due to high proportion of critically ill cases among patients with cardiac injury group, simultaneously with high 
leukocyte and hs-CRP, the immunosuppress medication such as glucocorticosteroids and immunoglobulin was 
widely used among these patients in this cohort at very early stage of COVID-19 outbreak.
These results emphasize the fundamental role of cardiac injury in deteriorating the clinical course of patients 
with COVID-19, and thus, close clinical monitoring and early intervention in case of cardiac injury are of utmost 
importance for management of these patients.
Cardiac injury and inflammation. The pathogenic mechanisms of cardiac injury caused by SARS-CoV-2 
remain  controversial20. A recent study identified that old age, comorbidities and CRP were risk factors of cardiac 
injury in patients with severe COVID-19 by multivariate regression  analysis14. However, most simultaneous 
blood testing results were not included in this model. In contrast, our study focused on the association of cardiac 
injury with other pathophysiological alterations such as renal and hepatic function, coagulation parameters, as 
well as inflammatory mediators, to reveal the potential mechanisms that may contribute to the cardiac injury 
development during the progression of disease.
The theory of inflammatory response inducing myocardial injury has been widely discussed including direct 
viral invasion of cardiomyocytes through ACE2 receptors and systemic inflammation (e.g. cytokine storm) induc-
ing cardiomyocyte  injury10,20. Serial cases studies reported myocardial involvement manifested as myocarditis-
like presentation or Tako-Tsubo  syndrome21–23. Likewise, cardiac infection by viral particles in endomyocardial 
biopsy was also observed by electron microscopy in a case  report24. Thus, myocarditis caused by virus directly 
attacking cardiomyocytes was inferred in these cases. However, autopsy examination also revealed interstitial 
immune cell infiltrates without substantial myocardial damage in patients with COVID-1925. Therefore, it can 
be speculated that typical myocarditis-like presentation does exist in some patients, but this mechanism is likely 
not responsible for the considerable proportion of hospitalized cases having cardiac injury.
Higher blood levels of inflammatory biomarkers (e.g. CRP) and cytokines (e.g. IL2, IL7, IL10, etc.) have been 
reported in COVID-19 patients admitted to the  ICU3, and IL6 and IL10 have been determined to be strong 
discriminators for severe disease and death, consistent with our  findings26,27. These discoveries consistently 
indicated intense systemic inflammatory response in severe COVID-19 cases. However, a direct connection 
between systemic inflammatory markers and cardiac injury has not been established. In our present study, IL6 
was generally increased among patients with COVID-19, and was further elevated in the non-survivor group 
compared to survivors, in accordance with a previous  study27. On the other hand, IL6 was comparable between 
patients with or without cardiac injury in our study. Likewise, another inflammatory biomarker hs-CRP was 
not significantly associated with cardiac injury in our multivariable regression model. Serial testing analysis 
also revealed that the dynamics of IL6 and hs-CRP were not consistent with cardiac biomarker changes during 
progression of cardiac injury. It is noteworthy that few patients (2 out of 10 cases) presented dramatic increase 
of IL6 along with cardiac injury progression, suggesting that small proportion of patients might indeed have 
cytokine storm in this process. This may explain the observed association of plasma inflammatory cytokines and 
cardiac injury among critically ill patients as reported  before28. Nevertheless, our result suggests that, in general, 
both systemic inflammation and cardiac injury are associated with disease severity and prognosis, but any direct 
correlations between systemic inflammation induced by viral infection and cardiac injury still remain to be elu-
cidated. Nevertheless, the localized inflammation, distinctive from the systemic inflammation, is non-negligible 
in the pathogenesis of cardiac injury. The evaluation of localized inflammation is not available in present study, 
but it is widely confirmed in the pathogenesis of cardiac thrombosis and endothelial dysfunction.
Cardiac injury and coagulation dysfunction. In this present study, old age, high leukocyte count and 
elevated levels of AST, serum ferritin and D-dimer were demonstrated to be independently associated with 
cardiac injury using different multivariable analyses. Of note, old age and D-dimer were also demonstrated to 
be strong risk predictors of in-hospital mortality using multivariate regression  analysis17,20. Moreover, it was 
reported that discrete changes in D-dimer levels were observed earlier in the course of disease preceding the 
rapid progression  stage20. In some patients, increased release of IL6 can also initiate coagulation activation and 
contribute to hypercoagulable state.
Serial blood testing analysis revealed that dynamic changes of D-dimer were highly consistent with disease 
severity as well as progression to deterioration or  recovery29. Our serial observations of coagulation parameters 
demonstrated highly synchronous alterations of D-dimer along with progression to cardiac injury, suggesting 
a strong correlation between them. Interestingly, we also observed that fibrinogen was dramatically decreased, 
while FDP was significantly increased in cardiac injury, suggesting a hyperfibrinolytic state at the time of car-
diac injury. Meanwhile, platelets were demonstrated to be reduced in cardiac injury individuals, which could 
be inferred that the hypercoagulable state depletes the platelets. Platelets are potentially involved in initiation of 
COVID-19 associated thrombosis, and may propagate coagulation such as primary and secondary haemostasis.
Coagulation abnormalities such as disseminated intravascular coagulation (DIC) and thrombotic disease 
manifested as elevated D-dimer and FDP have been reported to be highly prevalent in COVID-19, but these 
were rarely observed for other coronavirus  infections29,30. The incidence of DIC was demonstrated to be very 
high (71.4%) in non-survivors18. Nevertheless, the pattern of DIC in COVID-19 seems to differ from DIC that 
occurs during sepsis since there is a more profound elevation of D-dimer as compared to thrombocytopenia in 
this disease. The hypercoagulable state may contribute to the formation of occlusive thrombus, which causes 
acute myocardial ischemia in patients with pre-exiting cardiovascular disease.
A newly proposed mechanism in the pathogenesis of COVID-19 is endothelial involvement or endothelii-
tis causing microcirculatory dysfunction across different organ  systems31, which may in turn contribute to 
coagulation disorder. This theory was based on direct viral infection of endothelial cells and diffuse endothelial 
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inflammation observed from histopathology examination of COVID-19 patients. Our recently published study 
showed that myocardial pericytes (a perivascular cell type that wrap around capillaries), which show strong ACE2 
expression, may be the potential targets of SARS-CoV-2, inducing microvascular  dysfunction9. The involve-
ment of coronary microcirculation along with the hypercoagulable state during COVID-19 may then result in 
a thrombotic microangiopathy, leading to myocardial injury.
With better understanding of coagulation dysfunction in COVID-19, there has already been an increasing use 
of anticoagulant therapy in management of these patients. An early large observational cohort study revealed that 
systemic anticoagulation was associated with improved survival in hospitalized COVID-19  patients32. In a more 
recent large retrospective cohort (n = 4389), anticoagulation was associated with lower mortality and intubation 
among hospitalized COVID-19 patients. Compared with prophylactic anticoagulation, therapeutic anticoagu-
lation was associated with lower mortality, although not statistically  significant33. Several small retrospective 
cohort studies convinced the efficacy of anti-coagulation (e.g. heparin or enoxaparin) on COVID-19 patients 
with different degrees of  severity34–36. A series of randomized controlled trials have been initiated to assess the 
causal effects of anticoagulation in different therapeutic  regimens37–41, and the results will provide convinced 
evidences for the clinical utility of these drugs in the near future. Taken together, both microvascular endothelial 
injury and coagulation dysfunction might be novel potential mechanisms of cardiac injury in COVID-19, and 
anticoagulation treatment may play a beneficial role in the prevention of disease progression and avoidance of 
cardiac injury, and thus, may improve overall prognosis of patients with this disease.
Our study has several limitations. It was an observational study, and included only a limited number of cases 
from a single center. Most patients only had single time point measurements of cardiac injury biomarkers, and 
the cases in the longitudinal sub-group study were not sufficient. The clinical association studies of cardiac 
injury from larger multicenter cohorts are warranted to validate the direct connection between cardiac injury 
and coagulation. Our study identified the association of cardiac injury and coagulation biomarkers, and further 
histopathologic findings is needed about intravascular thrombi formation.
In summary, cardiac injury, manifested by elevation of cardiac biomarkers, is a common complication of 
COVID-19, and is an independent risk factor for in-hospital mortality. Old age, high leukocyte count, and high 
levels of AST, D-dimer and serum ferritin are significantly associated with cardiac injury. Multivariate regression 
analysis revealed old age and elevated D-dimer levels as being strong risk predictors of in-hospital mortality. 
Serial observations of coagulation parameters demonstrated highly synchronous alterations of D-dimer along 
with progression to cardiac injury. Therefore, the pathogenesis of cardiac injury in COVID-19 may be primarily 
due to coagulation dysfunction along with microvascular endothelial injury.
Methods
Study participants. This single-center, observational study included patients with COVID-19 who were 
admitted to the Jinyintan Hospital in Wuhan, China. We enrolled consecutive patients, who were diagnosed 
with this disease by SARS-CoV-2 viral nucleic acid test, from two patient wards of the hospital between January 
1, 2020, and February 27, 2020. All patients underwent cardiac biomarker testing at least once at admission or 
during later hospital stay. A part of the patients in this cohort have been included in our previous study about 
the electrocardiographic (ECG) characteristics of COVID-19 patients with cardiac  injury42. This study complied 
with the Declaration of Helsinki, and was approved by the Institutional Review Board of the Jinyintan Hospital 
Wuhan, China. Written informed consent was provided by patients, and informed consent statements were 
provided from legally authorized representatives for dead patients.
Clinical data collection. The demographic characteristics, clinical history, laboratory findings, treatment 
and complications for study participants were collected from electronic medical records during the patients’ hos-
pitalization by three investigators (J.T., W.H. and X.G.) who were blinded to the outcomes. The collected serum 
cardiac biomarkers included high-sensitivity troponin I (hs-TnI), myohemoglobin and creatine kinase-myocar-
dial band (CK-MB) in all patients. Cardiac injury was defined as elevation of at least one of the three cardiac 
biomarkers above the 99th percentile upper reference limit. Most clinical data (including laboratory findings) 
were collected at the time of admission, but if a patient developed cardiac biomarker elevation during hospi-
talization, the clinical data were later obtained at the time of cardiac injury. Patients were categorized according 
to the presence or absence of cardiac injury. The presence of acute respiratory distress syndrome (ARDS) and 
acute kidney injury and the degree of disease severity were defined as previously  reported2. Acute respiratory 
distress syndrome (ARDS) was defined according to the Berlin  definition43. Acute kidney injury was identified 
according to the Kidney Disease: Improving Global Outcomes  definition44. We defined the degree of severity 
of Covid-19 (severe vs. nonsevere) using the American Thoracic Society guidelines for community-acquired 
 pneumonia45. The clinical outcomes were defined as hospital discharge or death (recorded by N.H. and P.Z.). At 
the time of hospital discharge, all patients were relieved from clinical symptoms, and had normal body tempera-
ture, significant resolution of pulmonary findings by chest radiography, and at least two consecutive negative 
results of SARS-CoV-2 viral nucleic acid test. The data processing and statistical analysis were performed by an 
independent investigator (L.C.).
Statistical analysis. Continuous variables were presented as median (interquartile range [IQR]) values. 
Categorical variables were expressed as proportions. Comparisons between two groups were performed by 
Mann–Whitney U test for continuous variables or Fisher’s exact test for categorical variables, as appropriate. 
Paired Student’s t test was used to compare the serial results (from initial to cardiac injury) of cardiac biomark-
ers, cytokines and coagulation biomarkers. Spearman test was used for correlation analysis between cardiac 
biomarkers and other laboratory findings. Cox regression model was used to determine the risk factors of in-
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hospital mortality. The least absolute shrinkage and selection operator (LASSO) was used to determine nonzero 
coefficient features, which were considered as the most important factors of cardiac injury. Logistic regression 
model with odds ratio (OR) and 95% confidence intervals (CI) was used to determine the independent factors 
associated with cardiac injury, and to establish the prediction model of cardiac injury using the filtered features. 
Receiver operating characteristic (ROC) with area under curve (AUC) analyses were used to assess the predic-
tion value, and Youden’s index was used to determine the cut-off values with optimal sensitivity and specificity. 
We used SPSS 19.0 (IBM, US) for statistical analysis, and all statistical calculations followed a two-tailed test. A P 
value less than 0.05 was considered statistically significant. Statistical diagrams were plotted by Graphpad Prism 
5.0 (Graphpad Software, USA).
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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